Monday, June 30, 2025 8:55:57 PM
Longs know truly DISRUPTIVE change requires nurturing and a bit of growing roots below the surface, and when it emerges, it will be like a giant Moso Bamboo:
Running Bamboos primarily spread through extensive underground root systems called rhizomes. This is crucial for the plant to store energy and nutrients, and it can take a few years for a young plant to establish a robust rhizome system. During this initial period, you might see limited above-ground growth.
However once the underground rhizome system is well-established and conditions are favorable (typically in spring), the bamboo sends up new shoots (culms) from the nodes on these rhizomes. These new culms emerge from the ground at their full diameter and then grow to their mature height incredibly quickly, some species growing over 3 feet in 24 hours.
NWBO has been very active below the surface:
- vaccine (not drug)
- personalized, non-toxic, holistic response, immune memory
- broad spectrum cancer vaccine (DCs and MOA are tumor agnostic, stage agnostic)
- acquiring Flaskworks (automation, low cost mfg)
- acquiring Roswell Cancer Center's families of IP/patents for dendritic cells, including two Ph2 clinical trials
- first systemic drug treatment to achieve significant results in a Phase 3 clinical trial in decades for nGBM and rGBM
- built and own a state-of-the-art live cell mfg facility (Sawston, UK)
- next-gen DCVax-Direct product (Phase 2 trials about to begin)
- continual cutting-edge tech: genomic sequencing (Dr Ashkan), proteomics (Dr. Bosch), poly-iclc / adjuvants (Dr. Liau), tumor microenvironment (Roswell)
- creating a DCVax ecosystem ("Franchise")
- establishing a dominating moat in the DC therapy space
- MHRA Draft Guidelines on ECA, effective July 2025 (speculate NWBO participation)
- SI 2025 No 87, legislation for Modular Manufacturing and POC, effective July 2025 (speculate NWBO participation)
Due diligence + Investor calm = investing discipline.
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
